This
page is from a campaign
by award-winning investigative journalist Brian Deer in The
Sunday Times of London over
risks and side-effects
from this antibiotic, marketed
under many names, such as Bactrim,
Bactrim DS, Septra, Septra DS,
Septrin, Sulfatrim, SMZ/TMP,
Septran and co-trimoxazole | The investigation | Symptom searcher | Tell Brian & help others
Below are the texts of two
letters from some of the British
doctors who expressed outrage at
the challenge over a drug they
routinely prescribed.
|
|
|
From: Dr
Peter Newman BSc (Hons); MB.BS;
DRCOG; FPCertThorpe
Cloud, 6 Lakelands,
Hockwold-Cum-Wilton, Norfolk
March 3 1994
Dear Sir,
In your search
for journalistic truth, why do
you not spare a thought for
individual people's feelings.
Once again you
produce a story that will scare
many thousands of your readers.
|
Once
again you have jammed the phone systems
of many surgeries in the land. It is not
fair to continually print a piece of
sensationalist material.
As a
busy rural General Practitioner, I am not
happy at the implications or the
conclusions that you lead people to draw
from your article on
"Septrin/Bactrim".
You
mention the Committee on Safety of
Medicines, but you fail to even mention
that the number of serious adverse events
reported should be considered in the
light of the number of patients receiving
the medicine and the benefits derived
from treatment. It is important to
mention that adverse events are monitored
by a yellow card reporting system that to
date have been very effective in alerting
clinicians to adverse events of new
products.
I
find it intolerable that all you have
succeeded in doing is scaring the
majority of my patients, who may have had
some of these antibiotics in the past. I
am all for educating my patients but in
any counselling exercise you must provide
the patients with an informed benefits
and risks analysis and then let the
Patient decide, what course of action is
best.
It
is wise to remember that Health Care in
Medicine is a partnership between the
Doctor and the Patient and that informed
choice is the way forward.
Lastly,
I think that you are taking a very harsh
stance against one of the many very
Ethical Pharmaceutical Companies based in
this country. They have a very good
reputation for high standard of Research
& Development of new compounds. They
have made a significant contribution to
the area of Patient education and
continually strive to keep the Medical
Profession up to date with developments
and new information.
From:
Dr Andrew Melhuish, Henley Health
Concern, Wargrave, Berkshire
March
9 1994
Dear
Sir,
I am
a fifty-eight year old doctor in Henley
and have read the Sunday Times for most
of my life. I am in fact stopping reading
it now, transferring to The Observer, and
thought you would be interested in the
reasons.
A
small one is the size of the paper.
Having said that I understand the
pressures on you to produce a lot of copy
- but it is off putting, particularly
when Saturday's Times is also quite
bulky. I know a lot of my friends have
stopped getting a Sunday paper at all
because it is so large.
My
main reason however is the article which
appeared in the 27th February edition
with regards Septrin - by Brian Deer. I
do feel that a well balanced paper should
give two sides of an issue - otherwise
worry may be produced for readers. As a
GP I know a fair bit about Septrin, which
we have used in the practice for very
many years and which we monitor
carefully. It is our second most commonly
prescribed antibiotic behind Amoxicillin.
In addition many of my patients come out
from our local district hospital and from
the major London and Oxford hospitals on
this drug.
The
implication of your report was that we
are negligent in prescribing this drug.
It maybe that this is the case but we do
have, I think, a well run organisation
which looks at dangerous effects from
drugs run by Professor Bill Inman at
Southampton and also good objective
reviews of drugs through the Medical and
Therapeutics Bulletin which comes out
regularly. None of these have echoed the
comments made in the article.
Sulphonamides certainly have their
problems - but they also have real
advantages over other antibiotics, which
will be needed if we did not use Septrin.
This however is not really the case I
want to make. I feel that an opinion
explaining the other side of the issue
should have appeared with the article.
Certainly the article has worried many of
my patients, particularly a 16.5 year old
girl with cancer in her leg, under
treatment from the Middlesex Hospital,
and taking Septrin every day over quite a
long period. I do feel that this has not
improved the quality of what life she has
remaining.
|